Ser486

Site Information
QPEELVysQPEMRER SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 460854
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 )
Disease tissue studied:	melanoma skin cancer ( 8 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 1 , 3 , 5 ) , kidney ( 6 ) , MC3T3-E1 (preosteoblast) ( 2 ) , PYS-2 (epithelial) ( 7 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 8 )

Upstream Regulation
Treatments:	PTH(1-34) ( 2 )

References
1	Minard AY, et al. (2016) mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. Cell Rep 17, 29-36 27681418 Curated Info
2	Williams GR, et al. (2016) Exploring G protein-coupled receptor signaling networks using SILAC-based phosphoproteomics. Methods 92, 36-50 26160508 Curated Info
3	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
4	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
5	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
6	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
7	Zhou J (2010) CST Curation Set: 9108; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416 Curated Info
8	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
9	Guo A (2007) CST Curation Set: 3500; Year: 2007; Biosample/Treatment: cell line, E5 mLST8 deletion-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
10	Guo A (2007) CST Curation Set: 3501; Year: 2007; Biosample/Treatment: cell line, E5 mLST8 deletion-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
11	Guo A (2007) CST Curation Set: 3502; Year: 2007; Biosample/Treatment: cell line, E5/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
12	Guo A (2007) CST Curation Set: 3503; Year: 2007; Biosample/Treatment: cell line, E6-rictor-/-/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
13	Guo A (2007) CST Curation Set: 3504; Year: 2007; Biosample/Treatment: cell line, E6-rictor+/+/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
14	Guo A (2007) CST Curation Set: 3496; Year: 2007; Biosample/Treatment: cell line, E1-1796/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
15	Guo A (2007) CST Curation Set: 3497; Year: 2007; Biosample/Treatment: cell line, E1-1796/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
16	Guo A (2007) CST Curation Set: 3498; Year: 2007; Biosample/Treatment: cell line, E2-1802/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info
17	Guo A (2007) CST Curation Set: 3499; Year: 2007; Biosample/Treatment: cell line, E2-1802/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS/TF/Y) Immunoaffinity Beads Cat#: 1992 Curated Info